 PARIS, May 11, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS Euronext Growth: ALCLS, a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells UCART in the field of immuno-oncology, and Sanofi Euronext: SAN NYSE: SNY, today entered into a partnership agreement and a supply agreement regarding alemtuzumab, an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis sponsored UCART clinical trials. 